ClinicalTrials.gg
WithdrawnNCT03912792Updated Jul 2, 2019

A Cross-Sectional Natural History Study to Evaluate Sweat Volume and Other Phenotypic and Genetic Characteristics in Patients Affected by XLHED

An observational study in XLHED, sponsored by Dermelix Biotherapeutics, LLC.. Withdrawn at 1 site in United States. Open to participants aged Up to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-07-02.

Sponsored by Dermelix Biotherapeutics, LLC. · Observational

Why this study was withdrawn
Company decision
Study type
Observational
Model
Case-only
Time perspective
Other
Enrollment
0
Ages
Up to 80 Years
Sex
All
01

Study summary

The proposed natural history study will enroll male patients with a diagnosis of XLHED, female carriers of XLHED and healthy volunteers. The study protocol will include collection of XLHED questionnaires and clinical outcomes using minimally invasive technologies. Data will be collected both retrospectively and prospectively.

Clinical outcome assessments will be performed at the NFED Family Conference on July 11-12, 2019. Study participants will be able to complete XLHED questionnaires electronically ahead of the conference.

02

Conditions studied

  • XLHED

Keywords

  • Natural History Study
  • X-Linked Hypohidrotic Ectodermal Dysplasia
03

In context

Ectodermal Dysplasia 1, Anhidrotic

21 studies on the registry are indexed under Ectodermal Dysplasia 1, Anhidrotic; 1 is open to participants now.

Browse Ectodermal Dysplasia 1, Anhidrotic studies →

Lead sponsor

This is the only study on the registry with Dermelix Biotherapeutics, LLC. as lead sponsor.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Up to 80 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Males with XLHED and female carriers of XLHED

Male and female healthy volunteers

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Males with XLHED, female carriers of XLHED and healthy volunteers

Exclusion criteria

Exclusion Criteria:

  • Treatment with an study drug for XLHED
  • Any major medical problems that would prevent her/him from participating in this study
  • Known to pilocarpine or pilocarpine-like muscarinic agonists (Examples: Urecholine, Salagen, Pilocar, and Provocholine)
  • Pacemaker
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Observational model
Case-only
Time perspective
Other
Enrollment
0 participants (actual)
Patient registry
No

Groups and cohorts

  • XLHED Patients
  • Healthy Controls
06

What researchers measure

Primary outcomes

  1. The volume of sweat from a pilocarpine-induced sweat test

    Time frame: Day 1

07

Study locations

1 site
  • Chicago Marriott Lincolnshire Resort
    Lincolnshire, Illinois 60069, United States
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jul 2, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03912792
Lead sponsor
Dermelix Biotherapeutics, LLC.
Responsible party
Sponsor
First posted
Apr 11, 2019
Start date
Jun 28, 2019
Primary completion
Sep 2019 (estimated)
Completion
Sep 2019 (estimated)
Last update
Jul 2, 2019

Study contacts

Dorothy K Grange, MD
principal investigator · Washington University School of Medicine
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Jun 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion